Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli

Abstract Background Due to limited therapeutic options, the spread of extended-spectrum beta-lactamases (ESBLs) have become a major public health concern. We conducted a prospective, randomized, open-label comparison of the therapeutic efficacy of piperacillin-tazobactam (PTZ), cefepime, and ertapen...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Yu Bin Seo, Jacob Lee, Young Keun Kim, Seung Soon Lee, Jeong-a Lee, Hyo Youl Kim, Young Uh, Han-Sung Kim, Wonkeun Song
Format:	Artigo
Jezik:	Inglês
Izdano:	BMC 2017-06-01
Serija:	BMC Infectious Diseases
Teme:	Extended spectrum Beta-lactamase Piperacillin-tazobactam Cefepime Ertapenem
Online dostop:	http://link.springer.com/article/10.1186/s12879-017-2502-x
Oznake:	Označite Brez oznak, prvi označite!